KEYNOTE-355: pembro + chemo in triple-negative breast cancer

Latest in Immunotherapy for Breast Cancer in 2023Подробнее

GS1-02: "Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo..."Подробнее

KEYNOTE-355: outcomes in pts discontinuing chemo before pembro and in pts with immune-mediated AEsПодробнее

KEYNOTE-355: pembrolizumab in triple-negative breast cancerПодробнее

The evolution of immunotherapy for breast cancerПодробнее

KEYNOTE-355: HRQoL unaffected by the addition of pembrolizumab to chemotherapy for TNBCПодробнее

Pembrolizumab With Chemotherapy for TNBCПодробнее

Metastatic Triple Negative Breast Cancer Immunotherapy Treatment Options and Potential Side EffectsПодробнее

Highlights from SABCS 2021: T-DXd, KEYNOTE-355, PADA-1 & EMERALDПодробнее

Latest on Immunotherapy in Triple-Negative Breast Cancer - Medpage TodayПодробнее

Longer Overall Survival in Metastatic TNBC With Pembrolizumab - Medpage TodayПодробнее

SWOG Fall 2021 Virtual Group Meeting - Breast CommitteeПодробнее

ESMO 2021 breast cancer highlights: TULIP and KEYNOTE-355Подробнее

KEYNOTE-355: First-line pembrolizumab plus chemotherapy for metastatic triple-negative breast ca...Подробнее

#ESMO21 Highlights on combination of pembrolizumab plus chemotherapy in mTNBC: The KEYNOTE-355 studyПодробнее

Metastatic HER2 Negative Breast Cancer: Emerging Novel Treatment StrategiesПодробнее

Hope Rugo, MD, offers key takeaways for physicians regarding KEYNOTE-355Подробнее

Hope Rugo, MD, considers chemotherapy recommendations based on findings from KEYNOTE-355Подробнее

Hope Rugo, MD, shares the design and outcomes of KEYNOTE-355 presented at SABCS 2020Подробнее

FDA Approves pembrolizumab in Combination With ChemotherapyПодробнее